Harman Patil (Editor)

Delafloxacin

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Trade names
  
Baxdela

CAS Number
  
189279-58-1

Molar mass
  
440.76 g/mol

Legal status
  
Investigational

PubChem CID
  
487101

Delafloxacin httpsuploadwikimediaorgwikipediacommonsthu

Routes of administration
  
Oral, intravenous injection

Synonyms
  
ABT-492; RX-3341; WQ-3034

How to pronounce delafloxacin


Delafloxacin (INN) (tentative brand name Baxdela; former developmental code names ABT-492, RX-3341, WQ-3034), as the meglumine salt delafloxacin meglumine (USAN), is a fluoroquinolone antibiotic that is under development by Melinta Therapeutics (formerly Rib-X Pharmaceuticals) for the treatment of bacterial infections. As of December 2016, it is in Phase III clinical trials in the United States.

Contents

Delafloxacin is more active (lower MIC90) than other quinolones against Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). In contrast to most approved fluoroquinolones, which are zwitterionic, delafloxacin has an anionic character, which results in a 10-fold increase in delafloxacin accumulation in both bacteria and cells at acidic pH. This property is believed to confer to delafloxacin an advantage for the eradication of Staphylococcus aureus in acidic environments, including intracellular infections.

Clinical trials

Phase II clinical trials have been completed, including a trial with tigecycline as a comparator The company states delafloxacin met its primary and secondary efficacy endpoints based on the draft guidance from the FDA.

A Phase III trial for acute bacterial skin and skin structure infections (ABSSSI) is due to begin in the 2nd half of 2012.

References

Delafloxacin Wikipedia